Anti-CD28 Humanized Antibodies
AssigneesEffimune, Institut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsCaroline Mary, Nicolas Poirier, Bernard Vanhove
Life of this patent
Estimating the term…
Abstract
The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
Claims15
1-10. (canceled)
A method of treating a T lymphocyte-mediated autoimmune disease and/or a T-lymphocyte-mediated chronic inflammatory disease in a subject in need thereof comprising administering an anti-CD28 monovalent antibody to the subject, wherein the anti-CD28 monovalent antibody is selected from the group consisting of:
- (a) an antibody having a CD28-binding site consisting of:
- a heavy chain variable domain of SEQ ID NO:
- 1;
- and
- a light chain variable domain of SEQ ID NO:
- 2, and
- (b) an antibody having a CD28-binding site consisting of:
- a heavy chain variable domain having all three complementarity determining regions (CDRs) of the variable domain of SEQ ID NO:
- 1;
- and
- a light chain variable domain having all three CDRs of the variable domain of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.